Chris Waddell, Abbott’s U.S. VP for transcatheter aortic valve implantation (TAVI), posted the news on LinkedIn. It’s the latest milestone for Tendyne, a transcatheter mitral valve replacement (TMVR) system, after its FDA approval in May.

Dr. Frank Zidar, Dr. Faraz Kerendi, Dr. John Moscona and Dr. Stephen Dewan took part in the milestone procedure.

“All of us at Abbott are excited to share that the first U.S. commercial implantation of Tendyne, the only FDA-approved transcatheter mitral valve replacement system, was completed today at The Heart Hospital of Austin, Texas,” Waddell wrote. “Congratulations to [the doctors] as well as the entire Structural Team at Heart Hospital of Austin on completing this very significant milestone.”